Shawn Singh, VistaGen CEO (Jason Koerner/Getty Images for Concordia Summit)

Vista­Gen faces an­oth­er fail as anx­i­ety drug flops a PhI­II study — shares crater

Vista­Gen Ther­a­peu­tics’ so­cial anx­i­ety drug flopped in a Phase III tri­al, the com­pa­ny an­nounced Fri­day, adding to its list of pro­grams that haven’t panned out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.